British company Glaxo (GSK) just bought HIV assets from Bristol-Meyers Squibb. Now GSK and GILD can partner and control the HIV market and get tax benefits. Possible?
And cash on the books is approximately equal to the market cap based on everything I've read. Makes no sense.
A couple of days in the past week of approximately 4 million shares traded. I assume these are directed pre-arranged sales. Any guesses who is buying and who is selling?
Good news doesn't seem to be appreciated. $80 million in cash for a company with a $100 million market cap. Pfizer takes equity position and appears to "overpay." Great news on Fabry drug with huge market potential. NASH for liver disease. Other pipeline products to finish proof of concept trials by the end of this year. FDA meeting for Fabry drug within the next month or so. Amicus non-enzyme replacement Fabry drug delay. I don't understand the dropping price of the stock. I'm staying long. Maybe tax selling taking place?
I need help understanding today's news. Seems like PLX now has $80 million in cash with a market capitalization of $102 million. So if you back out the cash, the whole company is worth $22 million? Does this seem correct?
I have heard many of their scientific meetings and investor conferences over the past few years. They keep relating a very positive story. I would hate to think they were misrepresenting the facts but I share all of your concerns.
Amicus (FOLD) had bad news for their Fabry drug. Check it out. The stock is being crushed. Great timing for PLX. May be huge market opportunity. I hope the FDA wants to facilitate a new bio-better enzyme replacement therapy for the Fabry community. Approximately $1 Billion dollars per year spent on Fabry drugs from my understanding. More PLX news regarding Fabry trials is due out in the final quarter of this year (could be any day between now and year end).
I'm surprised the stock price has not risen more in response to hopeful ZTE court situation. I guess people would rather wait for a ruling. Such a low market cap that any significant settlement would cause the stock to bounce. I'm holding a position so I don't miss any move. I don't really view this as an investment but more as a bit of a gamble. Semantics but that's my mindset. I enjoy watching the news flow and really believe that the courts will ultimately recognize the value of patents and intellectual property so as not to discourage innovation.
63 cents. Take a shot with a few shares. Potential for a big pay day. Better odds than black or red. I would only commit money you can afford to lose. No point in selling now.
Good news out for Fabry. First potential bio-better with big market potential. The next few months will be interesting with good news flow.
I think the company claims to have enough cash for now. When they need cash to develop the oral anti- inflammatory (like Enbrel) and the inhaled cystic fibrosis drug, they will seek a suitable partner. The proof of concept for these two drugs should be done by the end of 2015 and suitable partners involved by early 2016. If necessary, a bit of dilution may be better than partnering too early.
Amicus stock has made a nice move as they promote their non-Enzyme Replacement Therapy for "amenable" Fabry patients. They are calling attention to the fact that most Fabry patients require ERTs and even those that don't may do better with Enzyme Replacement therapy. Protalix study results due out in the 3rd and 4th quarter for what seems to be an ERT bio-better compared to Sanofi (Genzyme) and Shire. Huge potential recurring market relative to Protalix's market cap. Protalix has great upside from this one drug and also becomes a prime takeover candidate for Sanofi, Shire or any Orphan drug company with an interest in protein synthesis.
$170 million market cap with a potential bio better for a $1 billion per year market for Fabry's. Proof of platform already done via FDA approval of Elelyso. Other pipeline products being developed. If Fabry data is good this stock can go much higher quickly.
New management seems to understand the need for better products not just cheaper ones.
I am a frustrated long-term holder just not willing to give up yet.
PLX opens at $2.15 on NYSE first day of Moshe Manor as CEO. I'm sure share price appreciation was on BOD minds when he was chosen. I wonder if he'll have anything top say about it at shareholders meeting next week.
I hold vrng stock with the hope that the case against Google is ultimately successful. But a part of me hopes the stock sells off significantly if En Banc is denied so I can triple down and buy more shares cheaply because the real story now is ZTE.
I will continue to hold some shares now hoping the Patent Office supports Vringo 's position publicly before the October 22nd deadline.
Any explanation of why Biocell redistributed its shares to the individual owners would be welcome. Seems like Biocell distributed shares at a low price possibly to avoid tax implications for the recipients.
Are we now ready for a new CEO to give us results of Oral Gauchers and Fabry trials? ZMapp still looking for a quick way to produce its drug?